Waldencast Announces Participation in the 2025 IMCAS World Congress
2025年1月29日 - 9:00PM
Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand
beauty and wellness platform, today announced its participation in
the 2025 International Master Course on Aging Science (IMCAS) World
Congress, which will be held in Paris from January 30, 2025 to
February 1, 2025.
The IMCAS World Congress is one of the most highly
anticipated events in the dermatology, plastic surgery, and aging
science community. It gathers industry leaders and executives to
discuss the latest breakthroughs, innovations, and business
opportunities.
Michel Brousset, Founder and Chief Executive
Officer, will participate in a capital markets roundtable where he
will discuss the future of medical grade skincare and the overall
beauty and aesthetics industry.
Additionally, Dr. Suzan Obagi, Chief Medical
Director at Obagi Medical, will participate in two sessions at the
event. The first is a lecture titled “Pairing Skincare with
Procedures to Enhance Results and Minimize Complications,” which
will focus on the complications of energy-based devices and how to
minimize the effects. The second is a scientific committee
symposium focused on hyperpigmentation.
About WaldencastFounded by Michel
Brousset and Hind Sebti, Waldencast’s ambition is to build a global
best-in-class beauty and wellness operating platform by developing,
acquiring, accelerating, and scaling conscious, high-growth
purpose-driven brands. Waldencast’s vision is fundamentally
underpinned by its brand-led business model that ensures proximity
to its customers, business agility, and market responsiveness,
while maintaining each brand’s distinct DNA. The first step in
realizing its vision was the business combination with Obagi
Skincare and Milk Makeup. As part of the Waldencast platform, its
brands will benefit from the operational scale of a multi-brand
platform; the expertise in managing global beauty brands at scale;
a balanced portfolio to mitigate category fluctuations; asset light
efficiency; and the market responsiveness and speed of
entrepreneurial indie brands. For more information please
visit: https://ir.waldencast.com/.
About Obagi MedicalObagi Medical
is an industry-leading, advanced skincare line rooted in research
and skin biology, refined with a legacy of 35 years’ experience.
First known as leaders in the treatment of hyperpigmentation with
the Obagi Nu-Derm® System, Obagi products are designed to
diminish the appearance of premature aging, photodamage, skin
discoloration, acne, and sun damage. Backed by science and trusted
by professionals, Obagi empowers individuals to achieve healthy,
beautiful skin. More information about Obagi is available on the
brand’s website, https://www.obagi.com.
About Suzan Obagi, MDSuzan Obagi,
MD Obagi is an Associate Professor of Dermatology and Plastic
Surgery at the University of Pittsburgh Medical Center (UPMC) and
serves as the director of the state-of-the-art UPMC Cosmetic
Surgery and Skin Health Center. Dr. Obagi's academic commitments
include clinical research, training residents in dermatologic
surgery & cosmetic dermatologic surgery, and in her role as the
director of the cosmetic dermatologic surgery fellowship.
Dr. Obagi has worked on various committees with the
American Society for Dermatologic Surgery, has formerly served as
vice president of the American Board of Cosmetic Surgery and the
President of the American Academy of Cosmetic Surgery, and is a
past president of the Cosmetic Surgery Foundation. In addition, Dr.
Obagi trains physicians from around the world on the latest in
cosmetic and laser surgery.
Contacts
InvestorsICRAllison
Malkininvestors@waldencast.com
MediaICRBrittany Fraser/Alecia
Pulmanwaldencast@icrinc.com
Waldencast (NASDAQ:WALD)
過去 株価チャート
から 2 2025 まで 3 2025
Waldencast (NASDAQ:WALD)
過去 株価チャート
から 3 2024 まで 3 2025